Botulinic toxin
PreclinicalSmall molecule
Botulinic toxin is one of 36 small molecule programs targeting Stroke. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1Activase
RochePreclinical
Zometa
PfizerPreclinical
Folvite
Eli LillyPreclinical
Proamatine
TakedaPreclinical
Repatha
AmgenPreclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Direct Anticoagulant
BayerPreclinical
Anticoagulants
SanofiPreclinical
Carbidopa-Levodopa
Neurocrine BiosciencesPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Botulinic toxin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity Hospital, Toulouse